Skip to content

Psilocybin: all studies

Page 274 of 440: studies 2,731 to 2,740 of 4,392, newest first. Back to the psilocybin overview

Research

Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways

Current Topics in Behavioral Neurosciences 2017 Juan F López-Giménez, Javier González-Maeso 302 citations

The neuropsychological effects of naturally occurring psychoactive chemicals have been recognized for millennia. Hallucinogens, which include naturally occurring chemicals such as mescaline and psilocybin, as well as synthetic compounds, such as lysergic acid diethylamide (LSD), induce profound alterations of human consciousness, emotion, and cognition. The discovery of the hallucinogenic...

Classical hallucinogens and neuroimaging: A systematic review of human studies: Hallucinogens and neuroimaging.

Neuroscience & Biobehavioral Reviews December 2016 Rafael G. Dos Santos, Flávia L. Osório, José Alexandre S. Crippa et al.

Serotonergic hallucinogens produce alterations of perceptions, mood, and cognition, and have anxiolytic, antidepressant, and antiaddictive properties. These drugs act as agonists of frontocortical 5-HT2A receptors, but the neural basis of their effects are not well understood. Thus, we conducted a systematic review of neuroimaging studies analyzing the effects of serotonergic hallucinogens in...

Psychedelics in the treatment of unipolar mood disorders: a systematic review

Journal of Psychopharmacology November 18, 2016 James Rucker, Luke A. Jelen, Sarah Kalen Flynn et al. 187 citations

Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used...

Psychedelics as Medicines: An Emerging New Paradigm

Clinical Pharmacology & Therapeutics November 4, 2016 De Nichols, Mw Johnson, Cd Nichols 366 citations

Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5‐HT 2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that...

Alterations of consciousness and mystical-type experiences after acute LSD in humans

Psychopharmacology October 7, 2016 Matthias E. Liechti, Patrick C. Dolder, Yasmin Schmid 203 citations

Mystical-type experiences were infrequent after LSD, possibly because of the set and setting used in the present study. LSD may produce greater or different alterations of consciousness at 200 μg (i.e., a dose that is currently used in psychotherapy in Switzerland) compared with 100 μg (i.e., a dose used in imaging studies). Ego dissolution may reflect plasma levels of LSD, whereas more...

Psychedelic Psychotherapy: Insights From 25 Years of Research

Journal of Humanistic Psychology September 29, 2016 William A. Richards 70 citations

Presented at a conference titled “Psychedelic Science 2013,” highlighting the resumption of investigations with psychedelic substances (i.e., psilocybin, DMT, LSD, MMDA, etc.) in the United States and Europe after a dormant period of more than two decades, the author presents insights and perspectives gleaned from his 25 years of clinical research experience. After acknowledging the vastness...

DOI: 10.1177/0022167816670996 (opens in new tab) Psilocybin Psychotherapist Consciousness Psyche +7

Hallucinogen Persistent Perception Disorder Induced by New Psychoactive Substituted Phenethylamines; A Review with Illustrative Case

Current Psychiatry Reviews August 10, 2016 Cornel N. Stanciu, Thomas M. Penders 3 citations

Hallucinogen Persistent Perception Disorder (HPPD) is considered an “uncommon” disorder described in association with use of hallucinogens such as LSD, mescaline and psilocybin. Despite multiple mentions of persistence of visual disturbances reported by users on online forums, clinicians may not be aware of this complication. There have been few descriptions of HPPD in association with use of...

Hallucinogens and dissociative drugs

Oxford University Press eBooks August 1, 2016 15 citations

Abstract Chapter 15 of Addiction Medicine covers hallucinogens and dissociative drugs. Hallucinogens are a large and diverse group of substances, some of which occur in fungi and plants and some which are chemically synthesized. Psychostimulants described in this chapter include psilocybin, mescaline, ayahuasca, lysergic acid diethylamide (LSD), and NBOMes and tryptamines. Dissociative drugs...

Hallucinogen Use Disorders.

Child and Adolescent Psychiatric Clinics of North America July 2016 Rashad Hardaway, Jason Schweitzer, Joji Suzuki

Use of hallucinogenic substances as a public health concern has increased over the past decade. Among adolescents, there are increasing emergency department presentations for intoxication with these drugs, contrary to decreasing reported use of classical hallucinogens such as LSD. Academic and governmental groups have monitored use of hallucinogens, highlighting a notable change in perceptions...

Entwicklung des Missbrauchs psychotroper Pflanzen und Pilze in Deutschland – Interpretation der Zahlen aus 3 Giftinformationszentren für die Jahre 2007–2013

Das Gesundheitswesen June 14, 2016 Jörg Pietsch, K. Scheffel, Daniela Acquarone et al. 2 citations

AIM OF THE STUDY: Based on an abundance of information on the internet, psychotropic plants and mushrooms are of increasing relevance as legal and cheap alternatives to other illicit drugs. Due to the lack of a German database, the abuse of selected biogenic drugs using reported exposures to 3 German Poison Information Centres (PICs) was examined. METHODS: Information on abuse of biogenic drugs...

DOI: 10.1055/s-0042-108644 (opens in new tab) Psilocybin Tropane Drugs of abuse Hallucinogen